Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study.
Yuki AkazawaAki YoshikawaMasaki KanazuYukihiro YanoToshihiko YamaguchiMasahide MoriPublished in: Thoracic cancer (2022)
TPS ≥ 90% and adenocarcinoma histology were independent risk factors for irAEs in previously untreated patients with advanced or recurrent NSCLC. Therefore, patients at high risk of irAEs require additional monitoring.